What is Aspira Pathlab & Diagnostics Ltd (540788) share price return in the past 10 years?

Data is not available for this company

What is the share price of Aspira Pathlab & Diagnostics Ltd (540788)?

Company share prices are keep on changing according to the market conditions. The current trading price of Aspira Pathlab & Diagnostics Ltd (540788) on 04-Sep-2026 16:59:59 at 16:59 is 97.00.

What is the P/E ratio of Aspira Pathlab & Diagnostics?

The latest standalone P/E ratio of Aspira Pathlab & Diagnostics as of 04-Sep-2026 is 0.00.

What is the P/B ratio of Aspira Pathlab & Diagnostics Ltd (540788)?

The latest standalone P/B ratio of Aspira Pathlab & Diagnostics Ltd (540788) as of 04-Sep-2026 is 8.19.

What is the 52-week high and low of Aspira Pathlab & Diagnostics Ltd (540788)?

The 52-week high of Aspira Pathlab & Diagnostics Ltd (540788) is Rs. 135.88 and the 52-week low is Rs. 49.00.

Aspira Pathlab & Diagnostics Ltd (540788)

Name: Aspira Pathlab & Diagnostics Ltd (540788)
Brand: Aspira Pathlab & Diagnostics

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540788 NSE: Hospital & Healthcare Services | Small Cap | Aspira Pathlab&Diagn Share Price

₹97 4.00 (4.30%)

As on 04-Sep'26 16:59

Aspira Pathlab & Diagnostics Ltd (540788)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540788 NSE: Hospital & Healthcare Services | Small Cap | Aspira Pathlab&Diagn Share Price

₹97 4.00 (4.30%)

As on 04-Sep'26 16:59

Key Metrics

Valuation Multiples

Market Cap

₹100 Cr.

Current Price

₹97

52-Week Low / High

₹49 / 136

TTM EPS

₹-0.4

TTM Sales

₹25.9 Cr.

Book Value per Share

₹11.9

P/E Ratio

0.00

Lower than its 5-year historical median

Industry PE

99.7

Price to Book (P/B)

8.19

Higher than its 5-year historical median

Price to Sales (P/S)

3.85

Higher than its 5-year historical median

EV/EBITDA

65.64

Higher than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

18.54%

Outperforms industry median

Return on Capital Employed (ROCE)

19.64%

Outperforms industry median

Return on Assets (ROA)

12.86%

Operating Profit Margin

16.2%

Net Profit Margin

9.42%

Gross Profit Margin

16.2%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

66.67%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

46.58%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹2 Cr.

Equity

₹10.3 Cr.

Face Value

₹10

All Time Low / High

₹14.15 / 135.88

Aspira Pathlab & Diagnostics stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Aspira Pathlab & Diagnostics Ltd a good quality company?

Aspira Pathlab & Diagnostics Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Aspira Pathlab & Diagnostics Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Aspira Pathlab & Diagnostics Ltd vs industry peers?

Aspira Pathlab & Diagnostics Ltd revenue CAGR is 21.18%, compared to the industry median CAGR of 3.54%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Aspira Pathlab & Diagnostics Ltd?

Promoters hold 46.58% of the Aspira Pathlab & Diagnostics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Aspira Pathlab & Diagnostics Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 9.52% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	1.8%	-25.4%	-38.4%	-34.5%	-26.3%	21.5%	41.6%	2.4%	-18.5%	19.6%	-
Value Creation Index ⓘ	-0.9	-2.8	-3.7	-3.5	-2.9	0.5	2.0	-0.8	-2.3	0.4	-
Growth Parameters ⓘ
Sales ⓘ	0	0.8	4.4	7.6	8.4	15.2	19.5	14.5	13.2	22	26
Sales YoY Gr.	-	NA	473.7%	75.2%	10.2%	80.6%	28.5%	-26%	-8.7%	66.7%	-
Adj EPS ⓘ	0.1	-5.3	-10.8	-6.3	-4.6	1.3	4.3	-0.1	-2.6	2	-0.4
YoY Gr.	-	-4475%	NA	NA	NA	NA	223.1%	-102.1%	NA	NA	-
BVPS (₹) ⓘ	16.2	11.4	0.6	6.3	4.1	8.1	12.4	12.4	9.9	11.9	11.9
Adj Net Profit ⓘ	0	-2.7	-5.6	-5.2	-4.2	1.4	4.5	-0.1	-2.7	2.1	-0
Cash Flow from Ops. ⓘ	-0.4	-1.3	-4.8	-3.4	-1.9	5.7	2	-0	1.1	1.9	-
Debt/CF from Ops. ⓘ	-7.2	-5.7	-2.4	-2.2	-4.2	0.2	0.4	-80.2	1	0.6	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	21.2%	4%	66.7%
Adj EPS ⓘ	37%	NA	-22.2%	NA
BVPSⓘ	-3.4%	23.8%	-1.5%	20.5%
Share Price	-	8.5%	36.7%	51.6%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	0.8	-57	-178.6	-187.6	-94.3	22.8	42.3	-0.7	-23.3	18.7	-3.7
Op. Profit Mgn % ⓘ	0	-339.5	-88.9	-42.5	-21.7	23.1	32.3	11	-9	16.2	3.8
Net Profit Mgn % ⓘ	0	-359.1	-128.1	-67.9	-50.4	9.1	22.8	-0.6	-20.2	9.5	-1.8
Debt to Equity ⓘ	0.7	1.2	33.9	1.5	2	0.2	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	0	1,188	353	244	224	89	91	175	187	127	35
Cash Conv. Cycle ⓘ	0	40	25	32	29	17	45	80	59	29	16

Valuation of Aspira Pathlab&Diagn - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0	0.76	4.36	7.64	8.42	15.21	19.54	14.46	13.20	22
Operating Expenses ⓘ +	0.23	3.34	8.23	10.88	10.24	11.69	13.23	12.86	14.39	18.47
Manufacturing Costs	0.03	0.20	0.65	0.84	0.83	2.48	1.78	1.08	1.96	3.41
Material Costs	0	0.14	1.30	2.26	1.99	2.63	3.14	2.50	2.62	3.70
Employee Cost	0.08	1.61	3.42	4.47	4.95	4.03	5.02	5.59	6.20	7.33
Other Costs ⓘ	0.13	1.38	2.85	3.31	2.48	2.55	3.29	3.70	3.61	4.04
Operating Profit ⓘ	-0.23	-2.58	-3.87	-3.25	-1.83	3.51	6.32	1.59	-1.19	3.52
Operating Profit Margin (%)	-	-339.0%	-88.9%	-42.5%	-21.7%	23.1%	32.3%	11.0%	-9.0%	16.0%
Other Income ⓘ +	0.32	0.31	0.22	0.25	0.29	0.20	0.15	0.32	0.42	0.39
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.05	0.26	0.80	0.96	1.01	0.89	0.37	0.42	0.37	0.35
Depreciation ⓘ	0	0.20	1.12	1.23	1.66	1.44	1.64	1.59	1.54	1.49
Profit Before Tax ⓘ	0.04	-2.72	-5.58	-5.18	-4.21	1.38	4.46	-0.09	-2.67	2.07
Tax ⓘ	0.01	-0	0	0	0.03	0	0	0	0	0
Profit After Tax	0.03	-2.72	-5.58	-5.18	-4.24	1.38	4.46	-0.09	-2.67	2.07
PAT Margin (%)	-	-359.0%	-128.0%	-67.9%	-50.4%	9.1%	22.8%	-0.6%	-20.2%	9.4%
Adjusted EPS (₹)	0.1	-5.3	-10.8	-6.3	-4.6	1.3	4.3	-0.1	-2.6	2.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3.64	5.92	0.33	5.19	3.80	8.31	12.79	12.75	10.14	12.22
Share Capital ⓘ	2.25	5.19	5.19	8.19	9.29	10.29	10.29	10.29	10.29	10.29
Reserves ⓘ	1.39	0.72	-4.86	-3	-5.49	-1.98	2.50	2.46	-0.15	1.92
Debt +	2.62	6.79	10.59	6.75	6.87	0.77	0.86	0.96	1.08	1.21
Long Term Debt	0	3.17	10.50	4.78	4.55	0.77	0.86	0.96	1.08	1.21
Short Term Debt	2.62	3.61	0.09	1.96	2.32	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0.29	0.23	0.29	0.40	0.66	0.61	0.35	0.73	0.74
Others Liabilities ⓘ	0.03	1.87	1.38	2.57	3.26	2.03	3.88	3.28	2.76	3.35
Total Liabilities ⓘ	6.30	14.86	12.53	14.80	14.34	11.78	18.14	17.34	14.71	17.51
Fixed Assets
Net Fixed Assets ⓘ +	0.04	7.79	7.91	8.90	8.70	7.75	9.57	8.01	6.79	6.53
Gross Block	0.04	7.99	9.23	11.45	12.91	13.41	16.87	16.88	17.20	18.31
Accumulated Depreciation	0	0.20	1.33	2.55	4.21	5.66	7.29	8.88	10.41	11.78
CWIP ⓘ	0	0.25	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0.13
Inventories	0	0.12	0.37	0.28	0.28	0.37	0.40	0.40	0.45	0.51
Trade Receivables	0.06	0.09	0.35	0.80	0.60	1.70	4.49	2.34	2.24	2.35
Cash Equivalents	5.33	2.81	0.22	0.10	1.10	1.19	1.64	2.35	1.38	2.14
Others Assets ⓘ	0.87	3.81	3.68	4.73	3.66	0.77	2.02	4.25	3.85	5.85
Total Assets ⓘ	6.30	14.86	12.53	14.80	14.34	11.78	18.14	17.34	14.71	17.51

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.37	-1.29	-4.81	-3.39	-1.87	5.67	2.03	-0.01	1.05	1.88
PBT ⓘ	0.04	-2.72	-5.58	-5.18	-4.21	1.38	4.46	-0.09	-2.67	2.07
Adjustment ⓘ	-0.02	0.15	1.71	1.99	2.40	2.36	2.40	1.80	1.77	1.78
Changes in Working Capital ⓘ	-0.33	1.29	-0.94	-0.19	-0.03	1.93	-4.83	-1.73	1.96	-1.97
Tax Paid ⓘ	-0.05	0	0	-0	-0.03	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.02	-10.14	-0.77	-1.97	0.24	-0.09	-0.51	0.16	0.14	0.07
Capex	-0.04	-8.20	-1	-0.51	-0.05	-0.30	-0.61	-0.13	-0.26	-0.17
Net Investments	0	-2.25	0	-1.71	0	0	0	0	0	-0.13
Others ⓘ	0.02	0.31	0.22	0.25	0.29	0.20	0.09	0.29	0.40	0.37
Cash Flow From Financing Activity ⓘ +	2.64	8.91	6.52	3.35	1.27	-2.17	-1.35	-0.94	-0.95	-0.99
Net Proceeds from Shares ⓘ	0	5	0	5.10	2.86	3	0	0	0	0
Net Proceeds from Borrowing ⓘ	2.62	3.17	7.33	-6.29	-0.23	-3.78	0.09	0.10	0.12	0.13
Interest Paid ⓘ	0	-0.26	-0.80	-0.96	-1.01	-0.89	-0.37	-0.42	-0.37	-0.35
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.01	0.99	-0	5.50	-0.34	-0.50	-1.07	-0.62	-0.70	-0.78
Net Cash Flow ⓘ	2.25	-2.52	0.94	-2	-0.35	3.41	0.17	-0.79	0.24	0.95

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.76	-57.04	-178.61	-187.57	-94.32	22.8	42.26	-0.69	-23.34	18.54
ROCE (%)	1.78	-25.35	-38.38	-34.5	-26.3	21.52	41.63	2.4	-18.49	19.64
Asset Turnover Ratio	0	0.07	0.32	0.56	0.58	1.16	1.31	0.82	0.82	1.37
PAT to CFO Conversion(x)	-12.33	N/A	N/A	N/A	N/A	4.11	0.46	N/A	N/A	0.91
Working Capital Days
Receivable Days	0	35.10	18.50	27.50	30.40	27.70	57.80	86.20	63.30	38.10
Inventory Days	0	57.30	20.50	15.50	12.10	7.70	7.20	10.10	11.70	8
Payable Days	0	736.30	72.10	41.70	63.30	73.90	74.10	69.80	74.60	72.30

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aspira Pathlab & Diagnostics Ltd FAQs

The current trading price of Aspira Pathlab&Diagn on 04-Sep-2026 16:59 is ₹97.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Sep-2026 the market cap of Aspira Pathlab&Diagn stood at ₹99.84 Cr

The latest P/E ratio of Aspira Pathlab&Diagn as of 03-Sep-2026 is 0.00.

The latest P/B ratio of Aspira Pathlab&Diagn as of 03-Sep-2026 is 8.19.

The 52-week high of Aspira Pathlab&Diagn is ₹135.9 and the 52-week low is ₹49.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aspira Pathlab&Diagn is ₹25.90 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Aspira Pathlab & Diagnostics Ltd is a below average quality company.

The key valuation ratios of Aspira Pathlab & Diagnostics Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aspira Pathlab & Diagnostics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited is a public limited company incorporated and domiciled in India. The company is engaged in the business of running, owning, managing and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.

It has its registered office at Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai, Maharashtra, India.

The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company’s performance, allocate resources based on the analysis of the various performance indicator of the Company as a single unit.

Business area of the company

The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Aspira Pathlab & Diagnostics Ltd (540788)

Aspira Pathlab & Diagnostics Ltd (540788)

Aspira Pathlab & Diagnostics stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Valuation of Aspira Pathlab&Diagn - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Financials

Equity and Liabilities

Fixed Assets

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aspira Pathlab & Diagnostics Ltd FAQs

About Aspira Pathlab & Diagnostics Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Aspira Pathlab & Diagnostics Ltd (540788)

Aspira Pathlab & Diagnostics Ltd (540788)

Aspira Pathlab & Diagnostics stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Valuation of Aspira Pathlab&Diagn - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Financials

Equity and Liabilities

Fixed Assets

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aspira Pathlab & Diagnostics Ltd FAQs

What is the share price of Aspira Pathlab&Diagn?

What is the market cap of Aspira Pathlab&Diagn?

What is the P/E ratio of Aspira Pathlab&Diagn?

What is the P/B ratio of Aspira Pathlab&Diagn?

What is the 52-week high and low of Aspira Pathlab&Diagn?

What is the TTM revenue of Aspira Pathlab&Diagn?

Is Aspira Pathlab & Diagnostics Ltd a good quality company?

Is Aspira Pathlab & Diagnostics Ltd undervalued or overvalued?

Is Aspira Pathlab & Diagnostics Ltd a good buy now?

About Aspira Pathlab & Diagnostics Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.